Amgen CTO David Reese to Retire, Responsibilities Split Among Three Executives
Amgen Inc. (NASDAQ: AMGN) announced a significant leadership restructuring on April 22, 2026, with Executive Vice President and Chief Technology Officer David M. Reese set to retire on June 30, 2026. The biotechnology giant will redistribute his responsibilities among three senior executives rather than appointing a direct replacement, signaling a strategic shift in how the company manages its technology and innovation functions.
The Change
Dr. Reese's retirement marks the end of his tenure as Amgen's Chief Technology Officer, with the company choosing not to maintain the CTO position as a standalone role. Instead, his responsibilities will be divided among three current executive vice presidents, effective June 1, 2026:
James E. Bradner will expand his role as Executive Vice President of Research and Development to include Artificial Intelligence and Data responsibilities. This consolidation positions Bradner to oversee the company's entire innovation pipeline from discovery through data analytics.
Murdo Gordon, Executive Vice President of Amgen Global Markets and Policy, will absorb commercial and policy-related technology functions, strengthening the alignment between technology initiatives and market strategies.
Peter H. Griffith, Executive Vice President and Chief Financial Officer, will take on technology responsibilities related to financial systems and operational efficiency, integrating technology decisions more closely with financial planning.
The transition period from June 1 to June 30 will allow Dr. Reese to remain employed as an Executive Vice President, ensuring a smooth handover of his duties. Upon his departure, Reese will receive retirement benefits as outlined in Amgen's 2026 Proxy Statement, confirming he meets the company's retirement eligibility requirements.
Background
While the SEC filing does not detail Dr. Reese's tenure or specific achievements at Amgen, his position as Chief Technology Officer placed him at the center of the company's technological transformation efforts. The CTO role at a major biotechnology company like Amgen typically encompasses oversight of research technologies, data infrastructure, artificial intelligence applications in drug discovery, and digital transformation initiatives.
The three executives assuming Reese's responsibilities bring diverse expertise to their expanded roles. James Bradner's background in research and development positions him to integrate technology more deeply into Amgen's drug discovery processes. Murdo Gordon's commercial and policy experience will help ensure technology initiatives align with market needs and regulatory requirements. Peter Griffith's financial acumen will be crucial in evaluating technology investments and ensuring operational efficiency.
Amgen's decision to redistribute rather than replace the CTO position reflects a broader trend in the pharmaceutical industry toward more integrated leadership structures. Companies increasingly recognize that technology cannot be siloed but must be woven throughout all aspects of the business, from research and development to commercial operations.
What It Means
This leadership restructuring signals Amgen's commitment to what the company describes as "further integration of our science, technology and data." By distributing CTO responsibilities across three senior executives, Amgen appears to be embedding technology leadership directly into its core business functions rather than maintaining it as a separate vertical.
The emphasis on artificial intelligence and data in Bradner's expanded title suggests Amgen is prioritizing AI-driven drug discovery and development—a critical competitive advantage in modern biotechnology. With AI becoming increasingly central to identifying drug targets, optimizing clinical trials, and predicting drug efficacy, having these capabilities directly under R&D leadership could accelerate innovation cycles.
For investors, this reorganization may indicate improved operational efficiency and faster decision-making. By eliminating a layer of leadership and integrating technology responsibilities into existing roles, Amgen could reduce bureaucracy and improve coordination across departments. The move also suggests confidence in the current executive team's ability to handle expanded responsibilities without external hiring.
The timing of this announcement—providing over two months' notice before Reese's retirement—demonstrates orderly succession planning. This measured approach should minimize disruption to ongoing projects and provide stakeholders with confidence in leadership continuity.
Looking ahead, the success of this restructuring will depend on how effectively the three executives coordinate their new technology-related responsibilities. While the integrated approach offers potential benefits, it also requires careful coordination to ensure no critical technology initiatives fall through organizational gaps. Investors should monitor upcoming earnings calls and strategic updates for evidence that this new structure is delivering on its promise of better integration and alignment.
The retirement of a C-suite executive and elimination of the CTO position represents a significant organizational change for Amgen. However, by redistributing responsibilities to seasoned executives already familiar with the company's operations, Amgen appears positioned to maintain momentum in its technology initiatives while potentially gaining efficiency through tighter integration with core business functions.